Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuronetics, Inc. - Common Stock (NQ:STIM)

2.900 +0.050 (+1.75%)
Streaming Delayed Price Updated: 12:21 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuronetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
New initiative aims to provide information and resources for teen mental health amidst rising public health concerns 
From Neuronetics
Via GlobeNewswire
Aetna Policy Update Expands TMS Availability for Adolescents With Depression
Coverage criteria consistent with recent FDA clearance for NeuroStar TMS 
From Neuronetics
Via GlobeNewswire
3 Neurotech Stocks Bridging Mind and Machine
These neurotech stocks stand at the cutting edge of healthcare, but early entrants in new fields tend to be long-term winners. 
Via InvestorPlace
Earnings Outlook For Neuronetics
 
Via Benzinga
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal 
From Neuronetics
Via GlobeNewswire
BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents
Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health 
From Neuronetics
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news worth reading this morning! 
Via InvestorPlace
NeuroStar® Launches Better Me Provider Program Nationwide
The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry 
From Neuronetics
Via GlobeNewswire
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024 
From Neuronetics
Via GlobeNewswire
Neuronetics And 3 Other Stocks Under $3 Insiders Are Buying
 
Via Benzinga
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older 
From Neuronetics
Via GlobeNewswire
Nasdaq Moves Lower; Great Lakes Dredge & Dock Shares Surge Following Upbeat Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Crude Oil Edges Lower; UBS Shares Jump After Q1 Earnings
 
Via Benzinga
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
STIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024
STIM stock results show that Neuronetics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance 
From Neuronetics
Via GlobeNewswire
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Lack of early symptom improvement is not predictive of final responder status 
From Neuronetics
Via GlobeNewswire
Top 5 Health Care Stocks That May Plunge In March
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older 
From Neuronetics
Via GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
From Neuronetics
Via GlobeNewswire
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
Advancements provide workflow efficiencies for NeuroStar® TMS providers 
From Neuronetics
Via GlobeNewswire
NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
Criteria Change Reduces Requirements for Treatment Accessibility 
From Neuronetics
Via GlobeNewswire
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
New accessory for NeuroStar TMS reduces patient setup steps and improves efficiency for providers 
From Neuronetics
Via GlobeNewswire
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
Technological advances reduce time and increase efficiency for MDD treatment 
From Neuronetics
Via GlobeNewswire
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
New updates designed to advance practice efficiency and patient outcomes 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives 
From Neuronetics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.